These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 26810815)

  • 21. Gadolinium Deposition in the Brain: A Systematic Review of Existing Guidelines and Policy Statement Issued by the Canadian Association of Radiologists.
    Costa AF; van der Pol CB; Maralani PJ; McInnes MDF; Shewchuk JR; Verma R; Hurrell C; Schieda N
    Can Assoc Radiol J; 2018 Nov; 69(4):373-382. PubMed ID: 30249408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gadolinium diffusion into orbital vitreous and aqueous humor, perivascular space, and ventricles in patients with chronic renal disease.
    Kanamalla US; Boyko OB
    AJR Am J Roentgenol; 2002 Nov; 179(5):1350-2. PubMed ID: 12388535
    [No Abstract]   [Full Text] [Related]  

  • 23. Gadolinium-based Contrast Media, Cerebrospinal Fluid and the Glymphatic System: Possible Mechanisms for the Deposition of Gadolinium in the Brain.
    Taoka T; Naganawa S
    Magn Reson Med Sci; 2018 Apr; 17(2):111-119. PubMed ID: 29367513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gadolinium deposition within the dentate nucleus and globus pallidus after repeated administrations of gadolinium-based contrast agents-current status.
    Stojanov D; Aracki-Trenkic A; Benedeto-Stojanov D
    Neuroradiology; 2016 May; 58(5):433-41. PubMed ID: 26873830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Impact of Gadolinium Deposition on Radiology Practice: An International Survey of Radiologists.
    Fitzgerald RT; Agarwal V; Hoang JK; Gaillard F; Dixon A; Kanal E
    Curr Probl Diagn Radiol; 2019; 48(3):220-223. PubMed ID: 29530452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gadolinium Retention in the Body and Brain: Is It Time for an International Joint Research Effort?
    Quattrocchi CC; van der Molen AJ
    Radiology; 2017 Jan; 282(1):12-16. PubMed ID: 28005498
    [No Abstract]   [Full Text] [Related]  

  • 27. Gadolinium Retention After Contrast-Enhanced MRI.
    Levine D; McDonald RJ; Kressel HY
    JAMA; 2018 Nov; 320(18):1853-1854. PubMed ID: 30208489
    [No Abstract]   [Full Text] [Related]  

  • 28. Survey of gadolinium-based contrast agent utilization among the members of the Society for Pediatric Radiology: a Quality and Safety Committee report.
    Blumfield E; Moore MM; Drake MK; Goodman TR; Lewis KN; Meyer LT; Ngo TD; Sammet C; Stanescu AL; Swenson DW; Slovis TL; Iyer RS
    Pediatr Radiol; 2017 May; 47(6):665-673. PubMed ID: 28283728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High Levels of Gadolinium Deposition in the Skin of a Patient With Normal Renal Function.
    Roberts DR; Lindhorst SM; Welsh CT; Maravilla KR; Herring MN; Braun KA; Thiers BH; Davis WC
    Invest Radiol; 2016 May; 51(5):280-9. PubMed ID: 26953564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gadolinium accumulation after contrast-enhanced magnetic resonance imaging: Which implications in patients with Crohn's disease?
    Savarino E; Chianca V; Bodini G; Albano D; Messina C; Tontini GE; Sconfienza LM
    Dig Liver Dis; 2017 Jul; 49(7):728-730. PubMed ID: 28506472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Review of the Current Evidence on Gadolinium Deposition in the Brain.
    Pullicino R; Radon M; Biswas S; Bhojak M; Das K
    Clin Neuroradiol; 2018 Jun; 28(2):159-169. PubMed ID: 29523896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pharmacokinetics of gadolinium-based contrast agents].
    Czock D
    Radiologe; 2019 May; 59(5):408-412. PubMed ID: 30725143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of Gadolinium Deposition in the Brain After MR Arthrography.
    Kralik SF; Singhal KK; Frank MS; Ladd LM
    AJR Am J Roentgenol; 2018 Nov; 211(5):1063-1067. PubMed ID: 30106613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Application of extracellular gadolinium-based MRI contrast agents and the risk of nephrogenic systemic fibrosis.
    Heverhagen JT; Krombach GA; Gizewski E
    Rofo; 2014 Jul; 186(7):661-9. PubMed ID: 24477507
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gadolinium deposition in the brain: another concern regarding gadolinium-based contrast agents.
    Karabulut N
    Diagn Interv Radiol; 2015; 21(4):269-70. PubMed ID: 26133320
    [No Abstract]   [Full Text] [Related]  

  • 36. Exceeding the limits of the normal blood-brain barrier: quo vadis gadolinium?
    Levy LM
    AJNR Am J Neuroradiol; 2007; 28(10):1835-6. PubMed ID: 17898191
    [No Abstract]   [Full Text] [Related]  

  • 37. NSF-active and NSF-inert species of gadolinium: mechanistic and clinical implications.
    Kuo PH
    AJR Am J Roentgenol; 2008 Dec; 191(6):1861-3. PubMed ID: 19020260
    [No Abstract]   [Full Text] [Related]  

  • 38. Free gadolinium is a likely trigger of nephrogenic systemic fibrosis.
    Abraham JL; Edward M
    AJR Am J Roentgenol; 2009 Oct; 193(4):W354; author reply W355. PubMed ID: 19770307
    [No Abstract]   [Full Text] [Related]  

  • 39. Advocating the Development of Next-Generation High-Relaxivity Gadolinium Chelates for Clinical Magnetic Resonance.
    Runge VM; Heverhagen JT
    Invest Radiol; 2018 Jul; 53(7):381-389. PubMed ID: 29462023
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of hepatobiliary gadolinium chelates for magnetic resonance imaging.
    Runge VM; Wells JW
    Acad Radiol; 1996 Aug; 3 Suppl 2():S455-7. PubMed ID: 8796628
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.